World Health Organization Sub-Types, Initial Treatment Outcome and Prognostic Study of Unselected Adult Patients with Acute Myeloid Leukaemia in Shanghai: An Analysis of 623 Cases

This study investigated the complete remission (CR) rate and survival of 623 newly diagnosed patients with acute myeloid leukaemia (AML) in Shanghai, China, classified according to World Health Organization and French–American–British criteria, and compared the differences in treatment effect with those reported in developed countries and those reported in Shanghai from 1984 to 1994. Total CR rate was 66.5%, median survival was 18 months and estimated survival at 3 years was 30.8%. The 3-year relapse rate was 55.1%. These data showed that the CR rate was similar to that achieved in studies from developed countries, but long-term survival was worse. The CR rate and survival were increased markedly compared with data previously collected in Shanghai (1984-1994). Induction chemotherapeutic regimens based on idarubicin, daunorubicin or homoharringtonine all had similar CR rates and survivals. Karyotype was the most important prognostic factor. Multilineage dysplasia in de novo AML was not an independent prognostic factor. Improvement in the long-term treatment effect in China is an important challenge for the future.

Download Full-text

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

Journal of Hematology & Oncology ◽

10.1186/s13045-016-0263-4 ◽

2016 ◽

Vol 9 (1) ◽

Cited By ~ 18

Author(s):

Lisa Pleyer ◽

Sonja Burgstaller ◽

Reinhard Stauder ◽

Michael Girschikofsky ◽

Heinz Sill ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

World Health Organization ◽

Myeloid Leukaemia ◽

Myelodysplastic Syndromes ◽

World Health ◽

Front Line ◽

Health Organization ◽

French American British ◽

Acute Myeloid

Download Full-text

Favourable prognostic factors in therapy related acute myeloid leukaemia

Srpski arhiv za celokupno lekarstvo ◽

10.2298/sarh1106347a ◽

2011 ◽

Vol 139 (5-6) ◽

pp. 347-352 ◽

Cited By ~ 2

Author(s):

Nebojsa Antonijevic ◽

Nada Suvajdzic ◽

Tatjana Terzic ◽

Branko Jakovljevic ◽

Gradimir Jankovic ◽

...

Keyword(s):

Prognostic Factors ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Radiation Treatment ◽

World Health ◽

Probability Of Survival ◽

Impact On Survival ◽

Cytogenetic Analyses ◽

Health Organization ◽

Acute Myeloid

Introduction. Therapy related acute myeloid leukaemia (t-AML) is a distinct clinical entity recognized by the World Health Organization classification occurring after chemotherapy and/or radiation treatment administered for a previous disease. T-AML is characterised by pancytopenia, three-lineage myelodysplasia, high frequency of unfavourable cytogenetics and short survival. Objective. The aim of this study was to analyse clinical, cytogenetic, and cytological characteristics of t-AML and their impact on survival. Methods. Seventeen patients with t-AML (8 male and 9 female; median age 59 years) were identified among 730 consecutive patients with acute myeloid leukaemia. The degree of three-lineage dysplasia as well as haematological, cytological and cytogenetic analyses, were assessed by standard methods. Results. The patients survived a median of 62.5 days with the 10% probability of survival during two years. Prognostically favourable factors were a higher percentage of dysplastic granulocytic cells, age less than 60 years, and presence of prognostically favourable karyotype inv(16), t(15;17), t(8;21). Conclusion. The stated prognostic factors that include age, cytogenetics findings and granulocytic dysplasia analysis could contribute to adequate risk stratification of t-AML, though fuller results would require additional analyses.

Download Full-text

Modern aspects of disability due to eye diseases

Kazan medical journal ◽

10.17750/kmj2015-224 ◽

2015 ◽

Vol 96 (2) ◽

pp. 224-226 ◽

Cited By ~ 2

Author(s):

M G Nazaryan ◽

P M Arbukhanova

Keyword(s):

Developing Countries ◽

World Health Organization ◽

Visually Impaired ◽

Low Vision ◽

Developed Countries ◽

Eye Diseases ◽

World Health ◽

The World ◽

Health Organization

Despite current successes of ophthalmology, during the last decades, blindness and low vision affect the population of both developed and developing countries. In United States, the prevalence of blindness in 1940 was 17.5 per 10 thousand in 1960-1979, this figure reached 20.0, and nowadays - 50.0 per 10 thousand. population. According to the World Health Organization data of 2014, the World has 285 million blind and visually impaired people, 90% of visually impaired live in developing countries. The main causes of blindness in underdeveloped and developing countries are cataract, trachoma, onchocerciasis, xerophthalmia. In highly developed countries, the causes are different - glaucoma, degenerative myopia, cataract, chorioretinal degeneration, diabetic retinopathy, congenital eye diseases. In the Russian Federation, the prevalence of blindness and low vision, as well as the structure of nosologies leading to these conditions are similar to those in developed countries. The prevalence of blindness and low vision in Russia, according to E.S. Liebman, for the 1985-2002 increased from 13.6 to 17.0 per 10 thousand, and the prevalence of blindness - from 7.0 to 7.8 per 10 thousand. The maximum rates observed in the Central and Volga economic regions (25.6 and 20.3), in the Udmurt Republic (39.6), Lipetsk (41.1) and Yaroslavl (34.3) regions (per 10 thousand). The World Health Organization has developed a long-term plan of action for the prevention of eye diseases in the global initiative «Vision 2020: the Right to Sight». A good progress has been made, particularly in combating infectious causes of blindness by supporting the Member States and attracting long-term resources. Thus, an active work is ongoing to reduce the disability due to eye diseases worldwide. Up to 80% of cases of blindness can be avoided with early diagnosis and treatment of patients.

Download Full-text

Evidence for a Clinically Distinct New Subtype of Grade II Astrocytomas in Patients with Long-term Epilepsy

Neurosurgery ◽

10.1227/01.neu.0000129546.38675.1b ◽

2004 ◽

Vol 55 (2) ◽

pp. 340-348 ◽

Cited By ~ 51

Author(s):

Johannes Schramm ◽

Cordelia Luyken ◽

Horst Urbach ◽

Rudolf Fimmers ◽

Ingmar Blümcke

Keyword(s):

Prognostic Factor ◽

World Health Organization ◽

World Health ◽

Term Survival ◽

Kaplan Meier ◽

Grade Ii ◽

Histological Characteristics ◽

Per Se ◽

Health Organization

Abstract OBJECTIVE: The authors tested the hypothesis that among Grade II astrocytomas with a particularly long seizure history, a subgroup is hidden with a different prognosis and possibly histological characteristics. To do so, clinical and histological characteristics of two groups of World Health Organization Grade II astrocytoma patients were analyzed: the long-term epilepsy-associated tumor (LEAT) astrocytoma group, with a mean duration of 12.5 years of seizures (n = 19), and the ordinary astrocytomas (n = 87), with a mean length of seizure history of 1.5 years (Non-LEAT). METHODS: All astrocytomas operated on between 1988 and 1999 were collected and followed up for 2 to 13 years (median, 7.0 yr). The 19 LEAT astrocytomas belonged to a group of 207 long-term epilepsy-associated tumors from the epilepsy surgery program. The 87 Non-LEAT cases were 60 so-called ordinary or diffuse World Health Organization Grade II astrocytomas and 27 oligoastrocytomas without long-term epilepsy operated on during the same time period. All tumor cases have been reviewed and partly reclassified as a result of the use of modern immunohistochemical techniques. Statistical analyses for possible discriminating factors included χ2 test, Fisher's exact test, Kaplan-Meier curves, and multifactorial analysis. RESULTS: Histological subtyping revealed a possible new isomorphic astrocytoma subtype in seven patients. By use of Kaplan-Meier curves, this isomorphic subtype had 50% fewer recurrences at 7.5 years and an estimated long-term survival of 80%. LEAT astrocytomas differed from ordinary Non-LEAT astrocytomas in overall length of history, younger age at first seizure, and higher percentage of 10-year survivors (80%). Temporal location did not influence outcome, and the presence of epilepsy per se was also not a prognostic factor. CONCLUSION: Differences between astrocytomas with a very long seizure history and those with a very short seizure history do exist. Significant factors for prognosis were age at surgery and presence of postoperative tumor residue but not the presence of epilepsy per se. A new subtype of astrocytomas, provisionally called isomorphic LEA astrocytoma, has putatively been identified with significantly better survival and lower recurrence rate. The negative prognostic factor of a gemistocytic differentiation pattern in diffuse astrocytomas was confirmed.

Download Full-text

Radioimmunotherapy for treatment of acute myeloid leukaemia and myelodysplastic syndrome

Nuklearmedizin ◽

10.1055/s-0038-1625714 ◽

2005 ◽

Vol 44 (03) ◽

pp. 107-117

Author(s):

R. G. Meyer ◽

W. Herr ◽

A. Helisch ◽

P. Bartenstein ◽

I. Buchmann

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Primary Tumour ◽

The Other ◽

Haematopoietic Stem Cell ◽

Other Hand ◽

Primary Reduction ◽

The One ◽

Acute Myeloid

SummaryThe prognosis of patients with acute myeloid leukaemia (AML) has improved considerably by introduction of aggressive consolidation chemotherapy and haematopoietic stem cell transplantation (SCT). Nevertheless, only 20-30% of patients with AML achieve long-term diseasefree survival after SCT. The most common cause of treatment failure is relapse. Additionally, mortality rates are significantly increased by therapy-related causes such as toxicity of chemotherapy and complications of SCT. Including radioimmunotherapies in the treatment of AML and myelodyplastic syndrome (MDS) allows for the achievement of a pronounced antileukaemic effect for the reduction of relapse rates on the one hand. On the other hand, no increase of acute toxicity and later complications should be induced. These effects are important for the primary reduction of tumour cells as well as for the myeloablative conditioning before SCT.This paper provides a systematic and critical review of the currently used radionuclides and immunoconjugates for the treatment of AML and MDS and summarizes the literature on primary tumour cell reductive radioimmunotherapies on the one hand and conditioning radioimmunotherapies before SCT on the other hand.

Download Full-text

Psychometric validation of the Chinese version of the PaArticular Scales among elderly residents in long-term care facilities with joint contractures

BMC Geriatrics ◽

10.1186/s12877-021-02297-5 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Yi-chang Chen ◽

Keh-chung Lin ◽

Chen-Jung Chen ◽

Shu-Hui Yeh ◽

Ay-Woan Pan ◽

...

Keyword(s):

World Health Organization ◽

Long Term Care ◽

Chinese Version ◽

World Health ◽

Term Care ◽

Joint Contractures ◽

The World ◽

Health Organization

Abstract Background Joint contractures, which affect activity, participation, and quality of life, are common complications of neurological conditions among elderly residents in long-term care facilities. This study examined the reliability and validity of the Chinese version of the PaArticular Scales in a population with joint contractures. Methods A cross-sectional study design was used. The sample included elderly residents older than 64 years with joint contractures in an important joint who had lived at one of 12 long-term care facilities in Taiwan for more than 6 months (N = 243). The Chinese version of the PaArticular Scales for joint contractures was generated from the English version through five stages: translation, review, back-translation, review by a panel of specialists, and a pretest. Test-retest reliability, internal consistency reliability, construct validity, and criterion validity were evaluated, and the results were compared with those for the World Health Organization Quality of Life scale and the World Health Organization Disability Assessment Schedule. Results The Chinese version of the PaArticular Scales had excellent reliability, with a Cronbach α coefficient of 0.975 (mean score, 28.98; standard deviation, 17.34). An exploratory factor analysis showed three factors and one factor with an eigenvalue > 1 that explained 75.176 and 62.83 % of the total variance in the Activity subscale and Participation subscale, respectively. The subscale-to-total scale correlation analysis showed Pearson correlation coefficients of 0.881 for the Activity subscale and 0.843 for the Participation subscale. Pearson’s product-moment correlation revealed that the correlation coefficient (r) between the Chinese version of the PaArticular Scales and the World Health Organization Disability Assessment Schedule was 0.770, whereas that for the World Health Organization Quality of Life scale was − 0.553; these values were interpreted as large coefficients. Conclusions The underlying theoretical model of the Chinese version of the PaArticular Scales functions well in Taiwan and has acceptable levels of reliability and validity. However, the Chinese version must be further tested for applicability and generalizability in future studies, preferably with a larger sample and in different clinical domains.

Download Full-text